Form 4: Celldex Therapeutics Executive Receives Stock Options

Teri Lawver, SVP & Chief Commercial Officer at Celldex Therapeutics, was granted 90,000 incentive stock options.

Summary

• Teri Lawver, Senior Vice President & Chief Commercial Officer of Celldex Therapeutics, Inc. (CLDX), was granted 90,000 incentive stock options.
• The options have an exercise price of $34.09 and were granted on June 25, 2026.
• These options are part of the company's 2021 Omnibus Equity Incentive Plan.
• Vesting begins with 25% on June 25, 2027, with the remainder vesting quarterly over the subsequent 12 quarters.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard executive compensation event rather than a significant financial or strategic development for the company.

Positives

• Grant of incentive stock options to a key executive, indicating management's commitment and alignment with shareholder value.
• The stock options are exercisable, providing potential future upside for the executive based on company performance.

Risks

• The value of the stock options is contingent on the future performance and stock price of Celldex Therapeutics.
• If the stock price does not exceed the exercise price of $34.09, the options may not be exercised profitably.

Future Outlook

The future outlook for the stock options is dependent on the company's stock performance and the executive's continued employment and vesting schedule.

Industry Context

StockSavvy.ai notes that the granting of stock options to senior management is a common practice in the biotechnology and pharmaceutical sectors to incentivize performance and align executive interests with those of shareholders, especially during periods of development and potential growth.

Stakeholder Impact

• Shareholders: The grant of options aligns executive interests with shareholder value, but the dilution from potential future exercise should be considered.
• Employees: May indicate a positive outlook for the company, potentially influencing morale and retention.
• Management: Provides a financial incentive for Teri Lawver to drive company performance.

Next Steps

• Monitoring the vesting schedule of the stock options.
• Observing the company's stock performance relative to the option exercise price.

Key Dates

Keywords

Celldex Therapeutics, CLDX, Form 4, Stock Options, Executive Compensation, Incentive Stock Option, Teri Lawver, Equity Incentive Plan, Vesting Schedule